Singulair and Suicide: FDA Strengthens Warning
The Carlat Psychiatry Report, Volume 18, Number 4, April 2020
https://www.thecarlatreport.com/newsletter-issue/tcprv18n4/
From The Carlat Psychiatry Report, April 2020, Psychopharmacology Algorithms
Issue Links: Learning Objectives | Editorial Information
After a rise of adverse psychiatric reports on montelukast (Singulair), an oral leukotriene inhibitor used for asthma and allergies, the FDA added a black box warning in March 2020 about mood and behavior changes including suicide.
You can't view details of this content, please login or buy subscription here